Showing 3971-3980 of 5623 results for "".
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Shamir Glacier Plus Metaform on Transitions Signature GEN 8 Brown and Grey Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-transitions-signature-gen-8-brown-and-grey-now-available/2481325/Shamir announced the launch of Shamir Glacier Plus Metaform, a new lens coating that is designed to remove compromises experienced with other lenses. According to Shamir, features of the coating include: Up to 20% thinner & lighter t
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of glaucoma during Glaucoma Awareness Month. “We are proud to collaborate with Glau
- Opus Genetics Acquires Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases from Iveric Biohttps://modernod.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1(BEST1)-related inherited retinal diseases a
- Study Identifies a Signaling Cascade Behind Retina Regeneration in Zebrafishhttps://modernod.com/news/study-identifies-a-signaling-cascade-behind-retina-regeneration-in-zebrafish/2481309/Experts at University of Michigan Medical School are investigating how Muller glial cells, responsible for regenerating a damaged zebrafish retina, acquire stem cell properties with the hope of eventually developing techniques to encourage human retinas to regenerate. Building
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Iveric Bio Completes Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481305/Iveric Bio announced that it has submitted to the FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.